Exicure Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • XCUR

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $11.50
  • (As of Thursday Closing)

Exicure General Information

Description

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Contact Information

Formerly Known As
AuraSense Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2430 North Halsted Street
  • Chicago, IL 60614
  • United States
+1 (847)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2430 North Halsted Street
  • Chicago, IL 60614
  • United States
+1 (847)

Exicure Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exicure Stock Performance

As of 06-Feb-2025, Exicure’s stock price is $11.50. Its current market cap is $34.9M with 2.61M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.50 $10.22 $1.44 - $36.00 $34.9M 2.61M 764K -$2.02

Exicure Financials Summary

As of 30-Sep-2024, Exicure has a trailing 12-month revenue of $500K.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 14,325 9,683 (2,485) (15,608)
Revenue 500 0 28,826 (483)
EBITDA (3,183) (15,571) 63 (60,773)
Net Income (4,007) (16,914) (2,582) (64,102)
Total Assets 10,631 11,580 23,328 64,868
Total Debt 6,128 6,665 7,306 14,736
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Exicure Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Exicure‘s full profile, request access.

Request a free trial

Exicure Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Exicure‘s full profile, request access.

Request a free trial

Exicure Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated
Drug Discovery
Chicago, IL
6 As of 2024

Wilmington, DE
 

Zug, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exicure Competitors (93)

One of Exicure’s 93 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
ImmunityBio Formerly VC-backed San Diego, CA
Dynavax Technologies Formerly VC-backed Emeryville, CA
PeproTech Corporate Backed or Acquired Cranbury, NJ
You’re viewing 5 of 93 competitors. Get the full list »

Exicure Patents

Exicure Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230330129-A1 Tumor necrosis factor receptor superfamily (tnfrsf) agonists, spherical nucleic acid (sna) tlr9 agonists and checkpoint inhibitors for antitumor therapy Inactive 11-Aug-2020
EP-4192477-A1 Treatment of skin diseases and disorders using inhibitors of kallikrein-related peptidases (klk) Inactive 07-Aug-2020
US-20220348917-A1 Liposomal spherical nucleic acid (sna) constructs for splice modulation Inactive 04-Sep-2019
US-20220362398-A1 Administration of spherical nucleic acids for ophthalmological uses Inactive 26-Apr-2019
EP-3923957-A4 Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy Inactive 12-Feb-2019 A61P35/00
To view Exicure’s complete patent history, request access »

Exicure Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exicure Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Exicure‘s full profile, request access.

Request a free trial

Exicure Acquisitions (1)

Exicure’s most recent deal was a Merger/Acquisition with Max-1 Acquisition. The deal was made on 27-Sep-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Max-1 Acquisition 27-Sep-2017 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Exicure’s complete acquisitions history, request access »

Exicure ESG

Risk Overview

Risk Rating

Updated November, 27, 2020

31.98 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,042

Rank

Percentile

Pharmaceuticals

Industry

of 947

Rank

Percentile

Biotechnology

Subindustry

of 427

Rank

Percentile

To view Exicure’s complete esg history, request access »

Exicure FAQs

  • When was Exicure founded?

    Exicure was founded in 2011.

  • Where is Exicure headquartered?

    Exicure is headquartered in Chicago, IL.

  • What is the size of Exicure?

    Exicure has 6 total employees.

  • What industry is Exicure in?

    Exicure’s primary industry is Drug Discovery.

  • Is Exicure a private or public company?

    Exicure is a Public company.

  • What is Exicure’s stock symbol?

    The ticker symbol for Exicure is XCUR.

  • What is the current stock price of Exicure?

    As of 06-Feb-2025 the stock price of Exicure is $11.50.

  • What is the current market cap of Exicure?

    The current market capitalization of Exicure is $34.9M.

  • What is Exicure’s current revenue?

    The trailing twelve month revenue for Exicure is $500K.

  • Who are Exicure’s competitors?

    Ayala Pharmaceuticals, CRISPR Therapeutics, ImmunityBio, Dynavax Technologies, and PeproTech are some of the 93 competitors of Exicure.

  • What is Exicure’s annual earnings per share (EPS)?

    Exicure’s EPS for 12 months was -$2.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »